Noorik Biopharmaceuticals is a clinical stage company based in Basel, Switzerland, dedicated to developing innovative therapies to address unmet medical needs. Their current focus is on the research and development of ambrisentan as a therapy for Portal Hypertension, a condition affecting the liver. Noorik was founded with the goal of utilizing the potential of existing drugs in new ways to improve patient outcomes.

Their commitment to research and development aims to make a positive impact on the lives of patients. To bring their groundbreaking treatments to market, Noorik is actively seeking a strategic commercialization partner. By joining forces with the right partner, they aim to transform their research into meaningful treatments that will benefit patients worldwide.

The company is led by a distinguished Board of Directors, including Mr. Elmar Schnee as Chairman, who brings extensive experience in the pharmaceutical industry. The CEO and Board Director, Dr.

Iker Navarro, has a background in clinical and drug safety roles, while Board Director Prof. Hans R. Brunner is a renowned expert in cardiovascular research.

Dr. Ernst Schweizer, another Board Director, possesses over 45 years of experience in the biopharmaceutical industry. Noorik Biopharmaceuticals is driven by their commitment to making a difference in the lives of patients and revolutionizing the field of drug development